Staying on track in a rapidly changing treatment landscape

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub spoke to Eunice Wang, Roswell Park Comprehensive Cancer Center, Buffalo, US, about the rapidly changing treatment landscape for patients with AML.

A number of exciting advances have been made in treatment approaches to AML over the past few years. Firstly, the phase III VIALE-A study, established venetoclax + azacitadine as a superior front-line induction treatment for elderly or unfit patients with AML. Furthermore, the oral hypomethylating agent, CC-486, became the first FDA approved maintenance strategy for AML.

The outlook for patients with P53 mutant AML has also improved. Two targeted therapies, APR-246 and magrolimab, have demonstrated encouraging response rates in this setting; a major advance in the treatment approach for patients with P53 mutant AML.

Eunice Wang concludes by outlining promising immunotherapeutic approaches to AML, including the CD33/CD3 bispecific antibody, AMG 330.